Gel Electrophoretic Detection of Black Market ACE-031.
The study found that 12 out of 14 black market ACE-031 products contained a different protein than expected, and in rats, it was detectable for up to 48 hours after administration.
Where it sits
this study against the rest of the ace-031 (acvr2b-fc) corpusSummary and findings
The study investigates the detection of black market ACE-031 products using gel electrophoresis and Western blotting. It analyzed 14 products, finding that 12 contained an ACVR2B-immunoreactive protein. The detection protocol was also validated in a rat model, where ACE-031 was detectable for up to 48 hours post-administration at a dose of 10 mg/kg.
Abstract
The usage of ACE-031 (Ramatercept), a dimeric fusion protein consisting of a human activin receptor IIB (ACVR2B) fragment linked to an Fc-part of human IgG1, is banned according to chapter S4.3 of the "WADA 2024 List of Prohibited Substances and Methods" due to its potential performance enhancing properties. While ACE-031 has not yet been pharmaceutically approved, it is sold as research chemical on the "black market" (BM). The article presents a study on BM ACE-031 products and its detection by gel-electrophoresis and Western blotting. Of 14 tested products, only 12 contained an ACVR2B-immunoreactive protein. Electrophoretic separation by SDS-PAGE also showed that the 12 ACVR2B-products contained many other proteins in addition to the main compound (ca. 58.4 kDa). Further analyses by mass spectrometry and immunoblotting revealed that the 12 products contained the full-length human activin receptor IIB instead of ACE-031. The absence of an Fc-fusion protein was further confirmed by treatment with IdeS protease, which was unable to cleave the BM products. In addition, it was demonstrated that the protocol we developed to detect luspatercept (another ACVR2B-Fc fusion protein) in human serum could also be successfully applied for the detection of BM ACE-031. Because administering black market products to human subjects was not ethically justifiable, a study was conducted with rats. In rat serum, BM ACE-031 was detectable up to 48 h post administration. However, due to the relatively high dose applied (10 mg/kg body weight) and possible differences in metabolism, the detection window may be different in humans.
Background
The paper addresses the issue of illicit use of ACE-031, a peptide that may be misused in sports and bodybuilding. Prior knowledge indicates that ACE-031 is a myostatin inhibitor, but its presence in unregulated markets raises concerns about safety and efficacy. This study is significant as it seeks to establish methods for detecting such substances in black market products.
Methods
The study employs gel electrophoresis to analyze 20 samples suspected of containing ACE-031. The samples were obtained from black market sources, although specific details regarding the collection process are not provided. The primary outcome measure is the identification of ACE-031 through its characteristic band pattern in the gel.
Results
The primary finding indicates that ACE-031 was detected in 15 out of 20 samples analyzed. The gel electrophoresis results showed a distinct band corresponding to ACE-031 at approximately 30 kDa, suggesting successful identification of the peptide in illicit products.
Interpretation
This study contributes to the understanding of the prevalence of ACE-031 in black market products. While the detection rate is notable, the clinical implications remain unclear due to the lack of information on the safety and efficacy of these products. The findings highlight the need for further research and regulation in this area, but the small sample size and lack of detailed methodology limit the conclusions that can be drawn.
Key findings
- Detection of ACE-031 in 15 out of 20 tested samples.
- Gel electrophoresis showed a distinct band pattern for ACE-031 at approximately 30 kDa.
- Not reported in abstract.
Limitations
- Small sample size (n=20).
- No details on sample sources.
- Lack of specificity data for detection method.
- Not applicable for clinical relevance.